Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 6/20 | 0.40 |
| ▸ | HRH1 | P35367 | 6/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 4/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22409434 | 1.00 | HRH2 (0.40) | HRH2HRH1SIGMAR1DRD2BCL2L1 | |
| SCHEMBL22409407 | 0.91 | DRD2 (0.40) | HRH2HRH1SIGMAR1DRD2BCL2L1 | |
| SCHEMBL22409406 | 0.91 | DRD2 (0.40) | HRH2HRH1SIGMAR1DRD2BCL2L1 | |
| SCHEMBL22409431 | 0.90 | SIGMAR1 (0.39) | HRH2HRH1SIGMAR1DRD2BCL2L1 | |
| SCHEMBL22409464 | 0.90 | SIGMAR1 (0.39) | HRH2HRH1SIGMAR1DRD2BCL2L1 | |
| SCHEMBL22409465 | 0.90 | SIGMAR1 (0.39) | HRH2HRH1SIGMAR1DRD2BCL2L1 | |
| SCHEMBL22409429 | 0.90 | SIGMAR1 (0.39) | HRH2HRH1SIGMAR1DRD2BCL2L1 | |
| SCHEMBL19014884 | 0.84 | BCL2L1 (0.38) | HRH2HRH1SIGMAR1DRD2BCL2L1 | |
| SCHEMBL30405586 | 0.83 | ATM (0.42) | SIGMAR1DRD2BCL2L1KDM4EATM | |
| SCHEMBL30405219 | 0.83 | ATM (0.42) | SIGMAR1DRD2BCL2L1KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | UNITY BIOTECHNOLOGY, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | UNITY BIOTECHNOLOGY, INC. | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111259-B2 | Acylsulfonamide derivatives for treating senescence-associated diseases and disorders | ACAT1, ARSA, GLA | HRH2 4378/4885HRH1 4590/4885SIGMAR1 4672/4885 |
| US-20200291050-A1 | ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS | ACAT1, ARSA, GLA | HRH2 4378/4885HRH1 4590/4885SIGMAR1 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.